25 XP   0   0   10

Eagle Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Eagle Pharmaceuticals Inc together

PenkeI guess you are interested in Eagle Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Eagle Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Eagle Pharmaceuticals Inc

I send you an email if I find something interesting about Eagle Pharmaceuticals Inc.

Quick analysis of Eagle Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Eagle Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.53
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
$17.88
Expected worth in 1 year
$35.30
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
$17.96
Return On Investment
409.1%

For what price can you sell your share?

Current Price per Share
$4.39
Expected price per share
$4.1 - $6.81
How sure are you?
50%

1. Valuation of Eagle Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$4.39

Intrinsic Value Per Share

$14.24 - $51.51

Total Value Per Share

$32.12 - $69.39

2. Growth of Eagle Pharmaceuticals Inc (5 min.)




Is Eagle Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$233.5m$176.4m$57.1m24.5%

How much money is Eagle Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money$35.6m-$8.6m$44.2m124.2%
Net Profit Margin11.3%-5.0%--

How much money comes from the company's main activities?

3. Financial Health of Eagle Pharmaceuticals Inc (5 min.)




What can you expect buying and holding a share of Eagle Pharmaceuticals Inc? (5 min.)

Welcome investor! Eagle Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Eagle Pharmaceuticals Inc.

What can you expect buying and holding a share of Eagle Pharmaceuticals Inc?

First you should know what it really means to hold a share of Eagle Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Eagle Pharmaceuticals Inc is $4.39. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Eagle Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Eagle Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $17.88. Based on the TTM, the Book Value Change Per Share is $4.36 per quarter. Based on the YOY, the Book Value Change Per Share is $0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.13 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Eagle Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps2.7362.1%2.7362.1%-0.66-15.1%1.2127.5%1.2428.3%
Usd Book Value Change Per Share4.3699.2%4.3699.2%0.010.3%1.3230.1%1.8842.8%
Usd Dividend Per Share0.133.0%0.133.0%0.184.2%0.122.7%0.061.4%
Usd Total Gains Per Share4.49102.3%4.49102.3%0.204.5%1.4432.9%1.9444.2%
Usd Price Per Share29.23-29.23-50.92-45.42-46.40-
Price to Earnings Ratio10.72-10.72--77.03-13.16-64.85-
Price-to-Total Gains Ratio6.51-6.51-258.67-56.14-40.49-
Price to Book Ratio1.64-1.64-3.77-3.48-5.28-
Price-to-Total Gains Ratio6.51-6.51-258.67-56.14-40.49-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.39
Number of shares227
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.130.12
Usd Book Value Change Per Share4.361.32
Usd Total Gains Per Share4.491.44
Gains per Quarter (227 shares)1,019.15327.61
Gains per Year (227 shares)4,076.591,310.46
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11213955406710912011300
22437910814421824032610
3364118661222132836043920
4486158211629843748055230
5607197762037554660066540
6728237312445265572087850
7850276862852976484099160
89713164132606873961010470
9109335597366839831081211780
101214395524076010921201313090

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%7.03.00.070.0%7.04.00.063.6%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%9.01.00.090.0%9.02.00.081.8%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%4.00.01.080.0%4.00.06.040.0%4.00.07.036.4%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%9.01.00.090.0%9.02.00.081.8%

Fundamentals of Eagle Pharmaceuticals Inc

About Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Fundamental data was last updated by Penke on 2024-04-11 06:44:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Eagle Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Eagle Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Eagle Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 11.3% means that $0.11 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Eagle Pharmaceuticals Inc:

  • The MRQ is 11.3%. The company is making a huge profit. +2
  • The TTM is 11.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ11.3%TTM11.3%0.0%
TTM11.3%YOY-5.0%+16.3%
TTM11.3%5Y7.0%+4.3%
5Y7.0%10Y-3.5%+10.4%
1.1.2. Return on Assets

Shows how efficient Eagle Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Eagle Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 8.8% Return on Assets means that Eagle Pharmaceuticals Inc generated $0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Eagle Pharmaceuticals Inc:

  • The MRQ is 8.8%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 8.8%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ8.8%TTM8.8%0.0%
TTM8.8%YOY-3.4%+12.2%
TTM8.8%5Y5.8%+3.0%
5Y5.8%10Y2.1%+3.7%
1.1.3. Return on Equity

Shows how efficient Eagle Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Eagle Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 15.3% Return on Equity means Eagle Pharmaceuticals Inc generated $0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Eagle Pharmaceuticals Inc:

  • The MRQ is 15.3%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 15.3%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.3%TTM15.3%0.0%
TTM15.3%YOY-4.9%+20.1%
TTM15.3%5Y8.9%+6.3%
5Y8.9%10Y-21.8%+30.8%

1.2. Operating Efficiency of Eagle Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Eagle Pharmaceuticals Inc is operating .

  • Measures how much profit Eagle Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Eagle Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 16.9% means the company generated $0.17  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Eagle Pharmaceuticals Inc:

  • The MRQ is 16.9%. The company is operating efficient. +1
  • The TTM is 16.9%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ16.9%TTM16.9%0.0%
TTM16.9%YOY-1.7%+18.6%
TTM16.9%5Y12.3%+4.6%
5Y12.3%10Y-3.7%+16.0%
1.2.2. Operating Ratio

Measures how efficient Eagle Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.74 means that the operating costs are $0.74 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Eagle Pharmaceuticals Inc:

  • The MRQ is 0.744. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.744. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.744TTM0.7440.000
TTM0.744YOY0.984-0.240
TTM0.7445Y0.845-0.100
5Y0.84510Y1.019-0.175

1.3. Liquidity of Eagle Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Eagle Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.70 means the company has $1.70 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Eagle Pharmaceuticals Inc:

  • The MRQ is 1.699. The company is able to pay all its short-term debts. +1
  • The TTM is 1.699. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.699TTM1.6990.000
TTM1.699YOY2.321-0.622
TTM1.6995Y3.426-1.727
5Y3.42610Y3.123+0.303
1.3.2. Quick Ratio

Measures if Eagle Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Eagle Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.15 means the company can pay off $1.15 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Eagle Pharmaceuticals Inc:

  • The MRQ is 1.150. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.150. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.150TTM1.1500.000
TTM1.150YOY1.933-0.783
TTM1.1505Y2.972-1.822
5Y2.97210Y2.839+0.133

1.4. Solvency of Eagle Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Eagle Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Eagle Pharmaceuticals Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.42 means that Eagle Pharmaceuticals Inc assets are financed with 42.5% credit (debt) and the remaining percentage (100% - 42.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Eagle Pharmaceuticals Inc:

  • The MRQ is 0.425. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.425. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.425TTM0.4250.000
TTM0.425YOY0.305+0.120
TTM0.4255Y0.323+0.102
5Y0.32310Y0.379-0.055
1.4.2. Debt to Equity Ratio

Measures if Eagle Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Eagle Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 73.9% means that company has $0.74 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Eagle Pharmaceuticals Inc:

  • The MRQ is 0.739. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.739. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.739TTM0.7390.000
TTM0.739YOY0.438+0.301
TTM0.7395Y0.489+0.250
5Y0.48910Y1.217-0.728

2. Market Valuation of Eagle Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Eagle Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Eagle Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 10.72 means the investor is paying $10.72 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Eagle Pharmaceuticals Inc:

  • The EOD is 1.609. Based on the earnings, the company is cheap. +2
  • The MRQ is 10.715. Based on the earnings, the company is underpriced. +1
  • The TTM is 10.715. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.609MRQ10.715-9.106
MRQ10.715TTM10.7150.000
TTM10.715YOY-77.033+87.748
TTM10.7155Y13.164-2.449
5Y13.16410Y64.853-51.689
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Eagle Pharmaceuticals Inc:

  • The EOD is 1.135. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 7.559. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 7.559. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.135MRQ7.559-6.424
MRQ7.559TTM7.5590.000
TTM7.559YOY23.823-16.264
TTM7.5595Y14.341-6.782
5Y14.34110Y-1.110+15.451
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Eagle Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Eagle Pharmaceuticals Inc:

  • The EOD is 0.246. Based on the equity, the company is cheap. +2
  • The MRQ is 1.635. Based on the equity, the company is underpriced. +1
  • The TTM is 1.635. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.246MRQ1.635-1.390
MRQ1.635TTM1.6350.000
TTM1.635YOY3.766-2.131
TTM1.6355Y3.484-1.849
5Y3.48410Y5.281-1.797
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Eagle Pharmaceuticals Inc.

3.1. Institutions holding Eagle Pharmaceuticals Inc

Institutions are holding 86.364% of the shares of Eagle Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc7.60060.00019849089582910.7785
2023-12-31HHG PLC5.98480.0024775525-365848-32.0533
2023-12-31Brandes Investment Partners & Co5.74990.0592745080-389283-34.3173
2023-12-31Vanguard Group Inc4.92450.0001638124-5473-0.8504
2023-12-31Millennium Management LLC4.03140.001252240217487050.3177
2023-12-31AQR Capital Management LLC3.80970.004949366521070774.4658
2023-12-31LSV Asset Management3.02320.0045391758-17000-4.1589
2023-12-31Goldman Sachs Group Inc2.99150.0002387648226395140.3974
2023-12-31Morgan Stanley - Brokerage Accounts2.29090.000129686413278980.9319
2023-12-31Renaissance Technologies Corp2.27230.00242944503829814.9513
2023-09-30Citadel Advisors Llc2.25460.001292160-101389-25.7627
2023-12-31Acadian Asset Management LLC2.21910.00582875555065321.3814
2023-12-31Dimensional Fund Advisors, Inc.1.90220.0004246497-34191-12.1811
2023-12-31J. Goldman & Co LP1.90170.05212464252464250
2023-12-31Geode Capital Management, LLC1.73860.000122529554512.4795
2023-12-31State Street Corporation1.71780.0001222594148237.1343
2023-12-31Two Sigma Advisers, LLC1.71330.0027222017199500885.9972
2023-12-31Assenagon Asset Management SA1.67980.00321766800
2023-12-31Two Sigma Investments LLC1.60220.0025207614174934535.2938
2023-12-31Bank of America Corp1.44280.00011869581822393861.8139
Total 60.85090.14297885207+839729+10.6%

3.2. Funds holding Eagle Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Janus Henderson US SMID Cap Growth3.91760.0391507646-204912-28.7572
2023-12-31Janus Henderson Triton D3.91760.0389507646-204912-28.7572
2024-02-29Vanguard Total Stock Mkt Idx Inv2.59890.000133676600
2024-03-28iShares Russell 2000 ETF1.93710.0022510131200.0478
2023-12-31Janus Henderson US Small Cap Growth1.70210.0378220561-139653-38.7695
2023-12-31Janus Henderson Venture D1.70210.0376220561-139653-38.7695
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.16470.000915091800
2024-01-31Fidelity Small Cap Index0.80010.002510367700
2024-03-29Avantis US Small Cap Value ETF0.79980.00510364200
2024-03-28iShares Russell 2000 Value ETF0.79680.0043103249-65-0.0629
2024-02-29SEI Small Cap F (SIMT)0.73210.09289486600
2024-03-28Invesco FTSE RAFI US 1500 Small-Mid ETF0.62870.01798146900
2023-06-30Columbia Trust Integrated Sm Cp Val Zero0.56290.48567293639866120.5503
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.54720.0017091200
2023-12-31AQR Small Cap Multi-Style I0.5320.342468942632681115.0511
2023-12-31Acadian Global Small-Cap Equity CIT Cl A0.47230.10046120700
2024-02-29Fidelity Extended Market Index0.44940.000958229-282-0.482
2023-12-31Kennedy Micro Cap0.42990.06155570141445290.7197
2024-03-31SEI Small Cap A (SIIT)0.40230.10815212828505.7835
2024-03-29Schwab US Small-Cap ETF™0.38790.00155026700
Total 24.48151.38033172336-541928-17.1%

3.3. Insider Transactions

Insiders are holding 12.023% of the shares of Eagle Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-01Scott TarriffSELL1092513.82
2023-10-02Scott TarriffSELL951115.23
2023-05-15Scott TarriffSELL1500021.07
2023-05-11Scott TarriffSELL1500020.71

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Eagle Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--4.3564.3560%0.013+33125%1.323+229%1.881+132%
Book Value Per Share--17.87617.8760%13.520+32%13.620+31%9.683+85%
Current Ratio--1.6991.6990%2.321-27%3.426-50%3.123-46%
Debt To Asset Ratio--0.4250.4250%0.305+40%0.323+31%0.379+12%
Debt To Equity Ratio--0.7390.7390%0.438+69%0.489+51%1.217-39%
Dividend Per Share--0.1340.1340%0.184-27%0.120+11%0.060+122%
Eps--2.7282.7280%-0.661+124%1.208+126%1.243+119%
Free Cash Flow Per Share--3.8673.8670%2.137+81%3.374+15%1.998+94%
Free Cash Flow To Equity Per Share--3.3923.3920%-0.038+101%0.798+325%1.331+155%
Gross Profit Margin--0.7620.7620%1.985-62%1.071-29%1.032-26%
Intrinsic Value_10Y_max--51.509--------
Intrinsic Value_10Y_min--14.241--------
Intrinsic Value_1Y_max--3.768--------
Intrinsic Value_1Y_min--1.873--------
Intrinsic Value_3Y_max--12.383--------
Intrinsic Value_3Y_min--5.275--------
Intrinsic Value_5Y_max--22.279--------
Intrinsic Value_5Y_min--8.264--------
Market Cap56886498.000-571%381904389.620381904389.6200%664561757.400-43%630566369.292-39%694860515.071-45%
Net Profit Margin--0.1130.1130%-0.050+145%0.070+61%-0.035+131%
Operating Margin--0.1690.1690%-0.017+110%0.123+37%-0.037+122%
Operating Ratio--0.7440.7440%0.984-24%0.845-12%1.019-27%
Pb Ratio0.246-566%1.6351.6350%3.766-57%3.484-53%5.281-69%
Pe Ratio1.609-566%10.71510.7150%-77.033+819%13.164-19%64.853-83%
Price Per Share4.390-566%29.23029.2300%50.920-43%45.418-36%46.402-37%
Price To Free Cash Flow Ratio1.135-566%7.5597.5590%23.823-68%14.341-47%-1.110+115%
Price To Total Gains Ratio0.978-566%6.5116.5110%258.674-97%56.143-88%40.491-84%
Quick Ratio--1.1501.1500%1.933-41%2.972-61%2.839-59%
Return On Assets--0.0880.0880%-0.034+139%0.058+51%0.021+309%
Return On Equity--0.1530.1530%-0.049+132%0.089+71%-0.218+243%
Total Gains Per Share--4.4904.4900%0.197+2181%1.443+211%1.941+131%
Usd Book Value--233560000.000233560000.0000%176453000.000+32%187192000.000+25%139182298.600+68%
Usd Book Value Change Per Share--4.3564.3560%0.013+33125%1.323+229%1.881+132%
Usd Book Value Per Share--17.87617.8760%13.520+32%13.620+31%9.683+85%
Usd Dividend Per Share--0.1340.1340%0.184-27%0.120+11%0.060+122%
Usd Eps--2.7282.7280%-0.661+124%1.208+126%1.243+119%
Usd Free Cash Flow--50523000.00050523000.0000%27896000.000+81%46925800.000+8%28947056.600+75%
Usd Free Cash Flow Per Share--3.8673.8670%2.137+81%3.374+15%1.998+94%
Usd Free Cash Flow To Equity Per Share--3.3923.3920%-0.038+101%0.798+325%1.331+155%
Usd Market Cap56886498.000-571%381904389.620381904389.6200%664561757.400-43%630566369.292-39%694860515.071-45%
Usd Price Per Share4.390-566%29.23029.2300%50.920-43%45.418-36%46.402-37%
Usd Profit--35642000.00035642000.0000%-8627000.000+124%17044000.000+109%19716152.700+81%
Usd Revenue--316610000.000316610000.0000%171546000.000+85%217032400.000+46%161035590.300+97%
Usd Total Gains Per Share--4.4904.4900%0.197+2181%1.443+211%1.941+131%
 EOD+4 -4MRQTTM+0 -0YOY+24 -125Y+27 -910Y+27 -9

4.2. Fundamental Score

Let's check the fundamental score of Eagle Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-151.609
Price to Book Ratio (EOD)Between0-10.246
Net Profit Margin (MRQ)Greater than00.113
Operating Margin (MRQ)Greater than00.169
Quick Ratio (MRQ)Greater than11.150
Current Ratio (MRQ)Greater than11.699
Debt to Asset Ratio (MRQ)Less than10.425
Debt to Equity Ratio (MRQ)Less than10.739
Return on Equity (MRQ)Greater than0.150.153
Return on Assets (MRQ)Greater than0.050.088
Total10/10 (100.0%)

4.3. Technical Score

Let's check the technical score of Eagle Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.923
Ma 20Greater thanMa 504.954
Ma 50Greater thanMa 1005.518
Ma 100Greater thanMa 2005.509
OpenGreater thanClose4.690
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Net Debt  -34,386-36,832-71,2185,157-66,061-5,991-72,05279,1977,145



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets406,160
Total Liabilities172,600
Total Stockholder Equity233,560
 As reported
Total Liabilities 172,600
Total Stockholder Equity+ 233,560
Total Assets = 406,160

Assets

Total Assets406,160
Total Current Assets188,754
Long-term Assets217,406
Total Current Assets
Cash And Cash Equivalents 55,321
Net Receivables 72,439
Inventory 47,794
Other Current Assets 13,200
Total Current Assets  (as reported)188,754
Total Current Assets  (calculated)188,754
+/-0
Long-term Assets
Property Plant Equipment 1,168
Goodwill 45,033
Intangible Assets 118,327
Other Assets 52,878
Long-term Assets  (as reported)217,406
Long-term Assets  (calculated)217,406
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities111,087
Long-term Liabilities61,513
Total Stockholder Equity233,560
Total Current Liabilities
Short-term Debt 6,250
Short Long Term Debt 6,250
Accounts payable 18,993
Other Current Liabilities 85,844
Total Current Liabilities  (as reported)111,087
Total Current Liabilities  (calculated)117,337
+/- 6,250
Long-term Liabilities
Long term Debt Total 56,216
Capital Lease Obligations Min Short Term Debt-927
Long-term Liabilities Other 5,297
Long-term Liabilities  (as reported)61,513
Long-term Liabilities  (calculated)60,586
+/- 927
Total Stockholder Equity
Common Stock18
Retained Earnings 111,504
Accumulated Other Comprehensive Income -1,112
Capital Surplus 366,265
Treasury Stock-243,115
Total Stockholder Equity (as reported)233,560
Total Stockholder Equity (calculated)233,560
+/-0
Other
Capital Stock18
Cash and Short Term Investments 55,321
Common Stock Shares Outstanding 13,065
Common Stock Total Equity18
Liabilities and Stockholders Equity 406,160
Net Debt 7,145
Net Invested Capital 296,026
Net Tangible Assets 70,200
Net Working Capital 77,667
Property Plant and Equipment Gross 7,769
Short Long Term Debt Total 62,466



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
> Total Assets 
9,438
18,103
53,411
124,605
213,570
270,060
238,603
254,554
253,190
253,732
406,160
406,160253,732253,190254,554238,603270,060213,570124,60553,41118,1039,438
   > Total Current Assets 
8,865
17,482
53,022
122,257
109,110
188,697
163,844
179,449
166,065
172,606
188,754
188,754172,606166,065179,449163,844188,697109,110122,25753,02217,4828,865
       Cash And Cash Equivalents 
5,067
10,456
22,722
79,083
52,820
114,657
78,791
109,775
103,155
97,659
55,321
55,32197,659103,155109,77578,791114,65752,82079,08322,72210,4565,067
       Short-term Investments 
1,500
0
19,999
0
0
0
0
0
0
4,983
0
04,98300000019,99901,500
       Net Receivables 
1,581
5,124
7,296
26,267
42,194
53,821
66,486
48,004
51,117
41,149
72,439
72,43941,14951,11748,00466,48653,82142,19426,2677,2965,1241,581
       Inventory 
87
1,871
1,294
15,042
2,739
5,118
8,304
6,566
8,075
21,908
47,794
47,79421,9088,0756,5668,3045,1182,73915,0421,2941,87187
       Other Current Assets 
138
32
1,711
1,865
11,357
15,101
10,263
15,104
1,605
11,890
13,200
13,20011,8901,60515,10410,26315,10111,3571,8651,71132138
   > Long-term Assets 
573
620
389
2,348
104,460
81,363
74,759
75,105
87,125
81,126
217,406
217,40681,12687,12575,10574,75981,363104,4602,348389620573
       Property Plant Equipment 
497
402
344
2,205
3,316
6,820
2,397
2,202
2,077
1,636
1,168
1,1681,6362,0772,2022,3976,8203,3162,205344402497
       Goodwill 
0
0
39,743
0
39,743
39,743
39,743
39,743
39,743
39,743
45,033
45,03339,74339,74339,74339,74339,74339,743039,74300
       Intangible Assets 
0
0
33,372
0
32,622
23,322
18,103
15,583
12,917
10,671
118,327
118,32710,67112,91715,58318,10323,32232,622033,37200
       Long-term Assets Other 
76
218
45
143
136
124
694
3,908
17,208
10,278
15,721
15,72110,27817,2083,9086941241361434521876
> Total Liabilities 
21,536
16,049
20,315
34,262
62,344
90,916
77,841
75,380
67,179
77,279
172,600
172,60077,27967,17975,38077,84190,91662,34434,26220,31516,04921,536
   > Total Current Liabilities 
20,882
14,342
20,315
34,262
40,215
47,302
39,686
38,823
38,085
74,376
111,087
111,08774,37638,08538,82339,68647,30240,21534,26220,31514,34220,882
       Short-term Debt 
8,572
3,060
9,226
-86
0
4,875
6,250
5,000
8,000
25,607
6,250
6,25025,6078,0005,0006,2504,8750-869,2263,0608,572
       Short Long Term Debt 
0
0
0
0
0
4,875
6,250
5,000
8,000
25,607
6,250
6,25025,6078,0005,0006,2504,87500000
       Accounts payable 
1,444
1,193
4,059
3,943
14,716
11,981
9,917
5,462
6,268
16,431
18,993
18,99316,4316,2685,4629,91711,98114,7163,9434,0591,1931,444
       Other Current Liabilities 
1,366
69
445
24,405
25,499
15,055
1,809
2,298
3,075
6,975
85,844
85,8446,9753,0752,2981,80915,05525,49924,405445691,366
   > Long-term Liabilities 
655
1,707
10,644
9,857
22,129
43,614
38,155
36,557
29,094
2,903
61,513
61,5132,90329,09436,55738,15543,61422,1299,85710,6441,707655
       Long term Debt Total 
0
0
0
0
0
42,905
38,155
33,557
25,135
0
56,216
56,216025,13533,55738,15542,90500000
       Long term Debt 
655
1,707
0
0
0
42,905
38,155
33,557
25,135
0
56,216
56,216025,13533,55738,15542,9050001,707655
       Capital Lease Obligations 
0
0
0
0
0
0
0
3,000
3,959
4,213
5,323
5,3234,2133,9593,0000000000
       Other Liabilities 
0
0
22,129
22,129
22,129
709
0
3,000
3,959
2,903
3,789
3,7892,9033,9593,000070922,12922,12922,12900
       Long-term Liabilities Other 
0
0
0
0
22,129
709
0
3,000
3,959
2,903
5,297
5,2972,9033,9593,000070922,1290000
> Total Stockholder Equity
-12,098
2,054
33,096
90,343
151,226
179,144
160,762
179,174
186,011
176,453
233,560
233,560176,453186,011179,174160,762179,144151,22690,34333,0962,054-12,098
   Common Stock
2
3
14
15
16
16
17
17
17
17
18
18171717171616151432
   Retained Earnings 
-95,537
-102,136
-104,177
-107,112
-25,659
26,284
58,187
72,500
84,489
75,862
111,504
111,50475,86284,48972,50058,18726,284-25,659-107,112-104,177-102,136-95,537
   Capital Surplus 
0
0
137,259
197,440
213,872
233,639
256,458
278,518
305,403
325,779
366,265
366,265325,779305,403278,518256,458233,639213,872197,440137,25900
   Treasury Stock-243,115-225,111-203,898-171,861-153,900-80,795-37,0030000
   Other Stockholders Equity 
83,438
104,187
137,259
197,440
176,869
152,844
102,558
106,657
101,505
100,668
123,150
123,150100,668101,505106,657102,558152,844176,869197,440137,259104,18783,438



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue316,610
Cost of Revenue-94,936
Gross Profit221,674221,674
 
Operating Income (+$)
Gross Profit221,674
Operating Expense-140,714
Operating Income53,45480,960
 
Operating Expense (+$)
Research Development34,088
Selling General Administrative98,126
Selling And Marketing Expenses8,500
Operating Expense140,714140,714
 
Net Interest Income (+$)
Interest Income271
Interest Expense-4,045
Other Finance Cost-0
Net Interest Income-3,774
 
Pretax Income (+$)
Operating Income53,454
Net Interest Income-3,774
Other Non-Operating Income Expenses-15,482
Income Before Tax (EBT)61,43345,475
EBIT - interestExpense = 49,409
61,433
39,687
Interest Expense4,045
Earnings Before Interest and Taxes (EBIT)53,45465,478
Earnings Before Interest and Taxes (EBITDA)65,478
 
After tax Income (+$)
Income Before Tax61,433
Tax Provision-25,791
Net Income From Continuing Ops35,64235,642
Net Income35,642
Net Income Applicable To Common Shares35,642
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring9,478
Other Operating Expenses235,650
Total Other Income/Expenses Net7,97919,256
 

Technical Analysis of Eagle Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Eagle Pharmaceuticals Inc. The general trend of Eagle Pharmaceuticals Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Eagle Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Eagle Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5.4 < 5.73 < 6.81.

The bearish price targets are: 4.1.

Tweet this
Eagle Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Eagle Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Eagle Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Eagle Pharmaceuticals Inc. The current macd is -0.25419782.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Eagle Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Eagle Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Eagle Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Eagle Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartEagle Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Eagle Pharmaceuticals Inc. The current adx is 19.09.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Eagle Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Eagle Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Eagle Pharmaceuticals Inc. The current sar is 5.26.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Eagle Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Eagle Pharmaceuticals Inc. The current rsi is 38.92. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Eagle Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartEagle Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Eagle Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Eagle Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Eagle Pharmaceuticals Inc Daily Stochastic Oscillator ChartEagle Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Eagle Pharmaceuticals Inc. The current cci is -146.07742026.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Eagle Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartEagle Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Eagle Pharmaceuticals Inc. The current cmo is -25.81795081.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Eagle Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartEagle Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Eagle Pharmaceuticals Inc. The current willr is -90.17857143.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Eagle Pharmaceuticals Inc Daily Williams %R ChartEagle Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Eagle Pharmaceuticals Inc. The current atr is 0.4282613.

Eagle Pharmaceuticals Inc Daily Average True Range (ATR) ChartEagle Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Eagle Pharmaceuticals Inc. The current obv is -7,421,517.

Eagle Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartEagle Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Eagle Pharmaceuticals Inc. The current mfi is 50.42.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Eagle Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartEagle Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Eagle Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-04MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Eagle Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Eagle Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.923
Ma 20Greater thanMa 504.954
Ma 50Greater thanMa 1005.518
Ma 100Greater thanMa 2005.509
OpenGreater thanClose4.690
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Eagle Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Eagle Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Eagle Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Eagle Pharmaceuticals Inc

I send you an email if I find something interesting about Eagle Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Eagle Pharmaceuticals Inc.

Receive notifications about Eagle Pharmaceuticals Inc in your mailbox!